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Abstract
Background: Chemo-radiotherapy offers an alternative to primary surgery and adjuvant therapy for the
management of locally advanced stage IV squamous cell carcinomas of the tonsil.
Methods: A retrospective analysis was performed of the outcomes of 41 patients with locoregionally advanced
squamous cell carcinoma of the tonsil treated non-surgically at the Yorkshire Cancer Centre between January 2004
and December 2005. Due to long radiotherapy waiting times, patients received induction chemotherapy with
cisplatin and 5-fluorouracil followed by either cisplatin concurrent chemoradiotherapy or radiotherapy alone.
Results: Median age was 55 years (range 34-76 years) and 28 (68%) patients were male. 35/41 patients (85%)
received 2 or more cycles of induction chemotherapy. Following induction chemotherapy, 32/41 patients (78%)
had a clinical response. Concomitant chemotherapy was given to 30/41 (73%). All patients received the planned
radiotherapy dose with no delays. There were no treatment related deaths. Six (15%) patients had gastrostomy
tubes placed before treatment, and 22 (54%) required nasogastric tube placement during or after treatment for
nutritional support. 17 patients required unplanned admissions during treatment for supportive care. At 4 months
post treatment assessment 35 out of 41 (85%) patients achieved complete clinical and radiographic response.
Median follow-up is 38 months (8-61 months). Local and regional control rate in complete responders at 3 years
was 91%. Distant metastases have been found in 4 (9.8%) patients. Three year progression-free survival rate in all
patients is 75%. The 3-year cause specific survival and overall survival are 75% and 66% respectively.
Conclusion: Cisplatin-based induction and concurrent chemoradiotherapy provides excellent tumour control with
acceptable toxicity for patients with locally advanced tonsillar cancer.
Introduction
Head and neck squamous cell carcinomas (HNSCC) are
the sixth most common cancers [1], with around two
thirds of patients presenting with locally advanced dis-
ease. The treatment of advanced disease poses a major
challenge in terms of balancing tumour outcomes with
acceptable toxicity and maintaining organ function [2,3].
For many years primary surgery and/or radiotherapy
have been the mainstay of treatment. Organ preservation
using radiotherapy has been accepted as an alternative to
surgery [4,5].
The role of chemotherapy has gradually emerged, and
is now taking a more prominent place in treatment
algorithms for locally advanced HNSCC. The use of
concurrent chemotherapy has improved locoregional
control, with optimal results being achieved with cispla-
tin [6-10]. Induction chemotherapy has been used in an
attempt to gain the benefit of full therapeutic doses of
chemotherapy via additive clonogen cell kill and spatial
cooperation to treat distant micro metastatic disease,
whilst avoiding the enhanced toxicity of concurrent
treatment [11]. The potential to reduce the risk of
developing distant metastases is particularly attractive as
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treatment. Meta-analyses have demonstrated a small
survival advantage of 2% with induction chemotherapy,
although cisplatin/5-FU regimens were associated with a
larger benefit in the order of 5% [6]. Recently, two
phase III studies have demonstrated an additional bene-
fit with the addition of docetaxel to cisplatin/5-FU
induction chemotherapy [12,13].
It has become evident that HNSCC represents a highly
heterogenous group of tumours. In order to improve the
therapeutic ratio of treatment it is critical to understand
the varied aetiology, biology and response to treatment
of tumours arising from different anatomical subsites. It
is therefore essential to report the outcome of treatment
for individual subsites, as opposed to simply grouping
them together. In this way, it may be possible to identify
tumour sites which would benefit from treatment inten-
sification, or alternatively tumour sites with a favourable
outcome for which a treatment de-escalation could be
considered to limit toxicity [2,3].
The oropharynx is a common head and neck cancer sub-
site accounting for just over 1000 cases each year in UK
[14]. Tonsillar tumours represent the most common site of
origin of tumours within the oropharynx, with a steadily
climbing incidence due in part to human papilloma virus
[15]. Non-surgical treatment plays a major role in the man-
agement of tonsillar squamous cell carcinomas (SCC).
A retrospective review [16] reported similar tumour con-
trol following primary surgery or radiotherapy in tonsillar
cancer; however, the risk of severe or fatal complications is
higher for patients treated surgically (> 20%) than those
treated with RT (2% - 11%). Currently, the choice of pri-
mary surgical or non-surgical treatment depends upon
local expertise, physician and patient preference.
Long radiotherapy waiting times have been a major
issue in UK [17]. In our regional cancer centre, radio-
therapy waiting times of around 3 months were preva-
lent at the time of this series, in common with many
other UK centres [18]. Delays in commencing radiother-
apy have associated with a decrease in local control
rates [19]. Locally advanced HNSCC were routinely
treated with induction cisplatin/5-FU chemotherapy in
order to avoid stage progression of tumours whilst
awaiting treatment. Concurrent chemotherapy was addi-
tionally administered depending upon tumour factors,
patient fitness and comorbidity.
Here we present the outcomes for patients with locally
advanced stage IV SCC of the tonsil managed with
induction chemotherapy followed by radical (chemo-)
radiotherapy. These data, in patients treated in routine
clinical practice, demonstrate the feasibility of adding
induction chemotherapy without compromising subse-
quent (chemo-)radiotherapy, and obtaining high rates of
tumour control without the need for surgery.
Materials and methods
From 1st January 2004 to 31st December 2005 patients
with a diagnosis of locally advanced stage IV tonsil
squamous cell carcinoma without distant metastases
who were treated at the Yorkshire Cancer Centre were
identified from the radiotherapy database. Patients who
received radical surgery and post-operative radiotherapy
were excluded from analysis. Data was obtained by a
retrospective review of the clinical notes, radiotherapy
and chemotherapy records, and the oncology patient
database. All patients were treated under the auspices of
the specialist Head and Neck multidisciplinary team, fol-
lowing a written protocol. Within this protocol, all
patients were investigated and staged with nasoendo-
scopy, biopsy, computed tomographic (CT) scanning
and/or magnetic resonance imaging (MRI) of head and
neck region, CT of thorax. Physical examination, dental,
dietary, speech and language assessment, full blood
count, electrolytes, liver and kidney function tests were
routinely performed before initiation of treatment. The
disease was staged according to the 2002 classification
of the American Joint Committee on Cancer Staging.
All patients were treated with induction chemotherapy
followed by concurrent chemoradiotherapy or radiother-
apy. Outcomes in terms of toxicity, site of relapse, dis-
ease free survival (DFS), and overall survival were
determined by a retrospective notes review, analysis of
radiotherapy treatment records, and oncology databases.
Toxicity was routinely documented prospectively using
the NCIC-version 3.0 grading system for chemotherapy
toxicity, and the RTOG system for radiotherapy toxicity.
Waiting time for radiotherapy was defined as the num-
ber of days from the clinic at which a decision was
made to treat with radiotherapy to the first day of
radiotherapy.
Induction chemotherapy
Standard induction chemotherapy consisted of 1-4
cycles of cisplatin 80 mg/m
2 day 1 and 5-fluorouracil
(5 FU) 800 mg/m
2 days 2-5, three weekly. Patients
underwent clinical, haematological and biochemical
assessment prior to each cycle; toxicity was prospec-
tively recorded. Further cycles were only given after
satisfactory toxicity assessment by medical staff. The
number of cycles administered depended upon the wait
until commencement of radiotherapy, tumour response
and toxicity.
Radiotherapy
All patients were treated with 3-dimensional conformal
radiotherapy. Patients were simulated supine using an
individualized neck support and Perspex shell for immo-
bilization. CT images for treatment planning were
obtained at 2-5 3 mm intervals from the skull vertex to
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Helax-TMS VG-1B treatment planning system. The tar-
g e tv o l u m ei n c l u d e dp r i m a r ys i t ea n db i l a t e r a ll e v e lI b ,
II, III, IV, V lymph nodes and retropharyngeal lymph
nodes. Treatment was planned with a two phase techni-
que of two parallel opposed photon fields, with a
matched anterior neck field. The posterior border of the
lateral 6MV photon fields was brought anterior to spinal
cord to avoid cord toxicity (after 39.75 Gy in 13 frac-
tions in the hypofractionated regimen or 44 Gy in
22 fractions in the conventionally fractionated regimen),
and matched electron fields were applied to the poster-
ior neck. Due to prevalent waiting times, radiotherapy
was booked prior to commencement of chemotherapy
and schedules based upon clinicians’ judgement/prefer-
ences and not upon chemotherapy responses. Two gen-
eral schedules were routinely used at the time: i) a
conventionally fractionated regimens of 65-70 Gy in
30-35 fractions over six and a half to seven weeks with
50 Gy in 25 fractions over five weeks to the matched
anterior neck, and ii) an accelerated hypofractionated
r e g i m e no f5 5G yi n2 0f r a c t i o n so v e rf o u rw e e k sw i t h
40 Gy in 15 fractions over three weeks to the matched
anterior neck. During radiotherapy, patients were
reviewed twice weekly, by a multidisciplinary team
involving clinician, nurse, dietician and speech and lan-
guage therapy team.
Concomitant chemotherapy
Cisplatin 80 mg/m2 days 1 and on the final day of radio-
therapy was used for accelerated hypofractionated radio-
therapy regimen. Cisplatin 100 mg/m2 days 1, 22 and 43
was used for the conventionally fractionated regimen.
Cisplatin was delivered with 2 litres pre-hydration and 2
litres post-hydration with normal saline during an over-
night inpatient stay. Carboplatin (area under curve 4)
was substituted for cisplatin if creatinine clearance was
<55 ml/min calculated by the Cockroft and Gault for-
mula and confirmed if time permitting by isotopic GFR
assessment. Full blood count, urea, serum creatinine
were checked prior to each course of chemotherapy.
Response assessment and Follow-up
After completion of therapy, each patient was followed
up clinically after 4-6 weeks to assess acute toxicity.
Tumour response was assessed 4 months after the com-
pletion of the treatment. Evaluation of tumour response
was routinely evaluated where indicated by a detailed
clinical examination of the head and neck, nasoendo-
scopy and CT or MRI imaging of the primary site and
the neck. An examination under anaesthetic and biop-
sies were performed in the event of clinical, nasoendo-
scopic or radiological abnormalities. Patients with less
than a complete response were evaluated for surgery.
Patients who were considered suitable for surgery by the
multi-disciplinary team underwent salvage surgery of
primary site and/or neck dissection. Subsequently,
patients were followed up with physical examination,
and flexible endoscopy every 6-8 weeks in the first year
after treatment, every 3 months for an additional 2
years, and every 6 monthly until discharge at 5 years.
Statistical analysis
The following endpoints were used for assessment:
induction chemotherapy response, overall treatment
response, progression-free survival (PFS), locoregional
recurrence-free survival (LRFS), distant metastasis-free
survival (DMFS), overall survival (OS) and cause specific
survival (CSS). PFS, LRFS, DMFS, OS and CSS were
analyzed using Kaplan-Meier product limit curves. Time
was measured from the date of diagnosis. Patients who
relapsed but for whom salvage therapy was successful
were still considered to have experienced failure at the
time of event occurrence. In the overall survival esti-
mates, deaths due to all causes are included in the cal-
culations. Significance of differences between survival
curves was calculated by the log rank test. A p value of
0.05 or less was declared statistically significant. Univari-
able analysis was performed stratified by tumour stage
(T stage), nodal stage (N stage) and treatment (induc-
tion chemotherapy followed by concurrent chemora-
diotherapy or induction chemotherapy followed by
radiotherapy alone).
Results
45 patients were identified who were treated with radio-
therapy for locally advanced stage IV tonsillar squamous
cell carcinoma. Four (9%) of these 45 patients were trea-
ted with primary surgery and received post-operative
radiotherapy and were excluded from analysis. Median
age of the remaining 41 patients was 55 years (range
34-76 years) and 28 (68%) patients were male. All 41
patients had pathologically confirmed squamous cell
carcinoma; 1 (2%) was grade 1, 12 (29%) were grade 2,
and 28 (68%) were grade 3. Patient characteristics are
shown in Table 1. All patients were non-metastatic
stage IV. Twenty-five (61%) patients had T3-4 primary
disease, while 39 (95%) had N2-3 lymph node disease.
Respective T and N stage distributions are detailed in
Table 2.
The median time between first clinic consultation to
the start of radiotherapy was 77 days (range 50-122 days).
All patients received cisplatin/5 FU induction chemother-
apy during this delay. 6 (14%) patients received one che-
motherapy cycle, 23 (56%) received two cycles, 10 (24%)
received three cycles and 2 (6%) patients received four
cycles. Fourteen (34%) of patients required an alteration
or dose reduction of chemotherapy treatment. Following
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indicated 32/41 patients (78%) had either a complete or
partial response. The responses to induction chemother-
apy are summarized in Table 3. Several different radio-
therapy schedules were used. 9 (22%) of patients received
an accelerated hypofractionated schedule of 55 Gy in 20
fractions over 4 weeks. The remaining 32 patients
received conventionally fractionated regimens (10
patients received 70 Gy in 35 fractions, 10 received 68 Gy
in 34 fractions, 8 received 66 Gy in 33 fractions and 4
patients received 65 Gy in 30 fractions. Due to radiother-
apy waiting times, radiotherapy schedules were booked
prior to the commencement of chemotherapy and were
hence based upon clincians’ judgement/preference rather
than response to induction chemotherpay. The median
time from the adminstration of the final cycle of induc-
tion chemotherapy to the first fraction of radiotherapy
was 21 days, with a range of 10-42 days.
Chemotherapy was administered concomitantly with
radiotherapy to 30 of 41 patients (73%). The decision
whether to administer concomitant chemotherapy was
made by the treating Clinical Oncologist, based upon
tumour and patient factors. These included age, perfor-
mance status, response and toxicity with induction che-
motherapy. The 11 patients who did not receive
concomitant chemotherapy had a median age of 58
(range 48-76); 8 of 11 had T3/4 disease (T4 n = 6) and
10 of 11 had N2/3 disease (N3 = 1). The 30 patients
treated with concomitant chemotherapy had a median
age of 54 (range 43-74); 17 of 30 had T3/4 disease (T4
n = 13) and 29/30 had N2/3 disease (N3 = 9). 4 of the 9
patients receiving hypofractionated radiotherapy with 55
Gy in 20 fractions over 4 weeks received concomitant
chemotherapy. 26 of 32 patients receiving conventionally
fractionated radiotherapy received concomitant
chemotherapy.
Of the 30 patients treated with concomitant che-
motherapy, 19 received only one of the planned cycles
of concurrent chemotherapy, while 11 of the 30 patients
completed two cycles of concurrent chemotherapy and
no patient received three. All of the 4 patients treated
with 55 Gy in 20 fractions over 4 weeks received only
one cycle of concomitant chemotherapy. Of the 26
patients receiving concomitant chemotherapy with con-
ventionally fractionated radiotherapy, 15 (58%) received
one cycle of chemotherapy and 11 received 2 cycles
(42%). Radiation therapy was completed in all patients
without any delays greater than 3 days. There were no
treatment related deaths.
Treatment Response
At 4 months post treatment assessment 35 (85%)
patients achieved complete clinical and radiographic
response (Table 3). The six (14%) remaining patients
achieved a partial response and were evaluated for sal-
vage surgery. Among these patients with a partial
response, neck dissections were performed in 2. Both
patients had had stable disease after induction che-
motherapy and neck dissection pathology showed exten-
sive nodal involvement with extra capsular spread. Both
patients died with locoregional recurrence and one of
them developed lung metastasis. The remaining
4 patients died with locoregional progression, with a
median survival of 10 months (range 8-14).
Survival outcomes
M e d i a nf o l l o w - u po fa l lp a t i e n t si s3 8m o n t h s( r a n g e
8-61 months). 27 (66%) patients remain alive, with a
median follow-up of 43 months (range 36-61 months).
Four patients (11%) have died during follow up follow-
ing a complete response to treatment without any evi-
d e n c eo fs u b s e q u e n td i s e a s er e c u r r e n c e .O n eo ft h e s e
patients died following a carotid blow out without evi-
dence of disease recurrence on post-mortem; the other
three deaths were due to myocardial infaction, Alzhei-
mer’s disease and a second primary tumour (adrenal).
Table 1 Patient characteristics
N%
Gender
Female 13 31.7
Male 28 68.3
Age (yrs)
≤60 yrs 31 75.6
>60 yrs 10 24.4
Table 2 Tumour characteristics
N classification
T classification N0 N1 N2 N3 Total
T1 --325
T2 --831 1
T3 --336
T4 1 1 15 2 19
Total 1 1 29 10 41
Table 3 Tumour responses assessed clinically after
induction chemotherapy, and clinically and radiologically
4 months after completion of radiotherapy
Complete
response N (%)
Partial
response
N (%)
Stable
disease
N (%)
After induction
chemotherapy
4 (10%) 28 (68%) 9 (22%)
4
th month after the
radiotherapy
35 (85%) 6 (15%) -
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ders at 3 years was 91% and median time to local and/
or regional recurrence was 20 months (range 13-23
months). Of the 35 patients with complete remission at
four month post-treatment assessment, one experienced
an isolated local failure, one an isolated regional failure,
one local and regional failure, one locoregional failure
with distant metastases. Among the three patients with
isolated local and/or regional recurrence, one has under-
gone salvage surgical resection after 13 months disease
free interval. Distant metastases were detected in
4 (10%) patients with a median 13 months of follow up
(range 7-27 months). Three of these four patients did
not experience locoregional failure. Three year distant
metastases free survival rate was 89%. Lung was the dis-
tant metastases site in all patients. Three years progres-
sion-free survival rate in all patients is 75%. The 2 and
3-year overall survival rate is 76% and 66% respectively,
and the 2 and 3-year cause specific survival rates are
80% and 75% respectively. Overall survival outcomes are
lower than cause specific outcomes due to the 4 deaths
during follow up without evidence of active disease.
Figure 1 shows the progression-free and cause specific
survival rates.
Prognostic factors
Univariable analysis revealed that the 3-year progres-
sion-free survival and cause specific survival were signif-
icantly better for patients with T1 and T2 disease
compared to T3 and T4 disease, respectively (p = 0.004
and p = 0.004). However, nodal stage and treatment
type did not show a significant association with progres-
sion-free survival, distant metastasis-free and cause spe-
cific survival. The association of T stage, nodal stage
and treatment type with PFS, DMFS, and CSS are given
in Tables 4.
Acute Toxicity
Induction chemotherapy
Grade 3 neutropenia occurred in 4 patients, 2 experi-
enced grade 3 mucositis.
(Chemo-)radiotherapy
Among the 30 patients who had concomitant chemora-
diotherapy, there was one case each of grade 3 vomiting
and of febrile neutropenia requiring admission. In 6 of 30
patients, carboplatin was substituted for cisplatin owing
to renal impairment. At the end of radiotherapy, in the
whole cohort of 41 patients RTOG grade 3 skin reaction
was documented in 31, and RTOG grade 3 mucosal toxi-
city in 29 patients. In the 9 patients receiving 55 Gy in 20
fractions over 4 weeks, 6 experienced RTOG grade 3 skin
toxicity and 7 experienced RTOG grade 3 mucositis. In
the remaining 32 patients receiving conventionally frac-
tionated radiotherapy, 25 experienced RTOG grade 3
skin toxicity and 22 had RTOG grade 3 mucositis.
Six (15%) patients had gastrostomy tubes placed pro-
phylatically before treatment. 22 (54%) of patients
required nasogastric tube (NG-tube) placement during
(n = 17), or after (n = 5) treatment for nutritional sup-
port. More than 10% weight loss during therapy was
seen in 10 (24%) patients. Seventeen patients required
admission for supportive care or nutrition during the
radiotherapy and 14 of these were treated with conco-
mitant chemoradiotherapy. 4 out of 9 (44%) patients
receiving 55 Gy in 20 fractions over 4 weeks and 19 out
of 32 (59%) patients receiving conventionally fractio-
nated radiotherapy required admission.
Late Toxicity
Among 27 surviving patients, as a long-term treatment-
related complication 2 patients have been recorded as
0
20
40
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100
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months
%
CSS
PFS
Figure 1 Cause specific survival and progression-free survival
in stage IV tonsil.
Table 4 Univariate analysis for progression-free survival
(PFS), distant metastasis-free (DMFS) survival and cause
specific survival (CSS) rates
PFS DMFS CSS
N 3 years
%
P 3 years
%
p 3 years
%
P
T stage
T1+T2 16 100 100 100
0.004 0.07 0.004
T3+T4 25 59 81 58
Nodal stage
N0-1 2 100 100 100
0.45 0.65 0.46
N2-3 39 74 89 73
Treatment
type
Induc CT-CTRT 30 72 89 72
0.6 0.59
Induct CT-RT 11 82 91 0.93 82
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gastrostomy tube dependent. Trismus has been docu-
mented in 4 patients. Four patients developed soft tissue
or osteoradionecrosis. One of them received 3 courses
of induction chemotherapy followed by concomitant
chemoradiotherapy died due to soft tissue, carotid artery
necrosis 7 months after the therapy.
Discussion
Concurrent chemo-radiotherapy has been widely
adopted as the standard of care for locally advanced
HNSCC [6,7]. Cisplatin is the chemotherapy agent of
choice, with studies showing a 5-12% improvement in
long term survival with standard or altered fractionation
regimens [6,8]. The improvement in survival comes at
the expense of increased acute and late toxicity [8,20].
Induction chemotherapy followed by sequential radio-
therapy is an alternative approach to concurrent treat-
ment which has been shown to have a survival benefit
in locally advanced HNSCC [21-23]. Although induction
chemotherapy has only a minimal survival benefit of 2%
in a large meta-analysis, the combination of cisplatin
and 5-FU was associated with a 5% survival benefit [6].
Two phase III studies have subsequently demonstrated
that induction chemotherapy with docetaxel, cisplatin
and 5-FU (TPF) offers a significant survival advantage
over induction with cisplatin and 5-FU [12,13]. In
patients with unresectable HNSCC, induction with TPF
resulted in a 27% reduction in the risk of death after a
median of 32 months follow-up [13]. Similarly, in the
study based in the US, 3 year overall survival with TPF
induction was 62% compared with 48% in the cisplatin
and 5-FU induction group [12].
One major concern with the addition of induction
chemotherapy is that it may compromise the ability to
deliver radiotherapy. In the EORTC/TAX323 study
examining induction chemotherapy, it is notable that
only 120 of 179 patient receiving cisplatin and 5-FU,
and 129 of 173 patients receiving TPF, ever received
radiotherapy [13]. The failure of such a significant pro-
portion of patients to ever receive the potentially cura-
tive part of the treatment schedule is a major concern
with induction chemotherapy. A further potential disad-
vantage of induction chemotherapy is that the ability to
deliver concurrent chemotherapy may be compromised.
The role of systemic treatment in addition to radio-
therapy in locally advanced HNSCC continues to
develop. Concurrent chemo-radiotherapy remains a
standard of care, while induction chemotherapy has
clear evidence of efficacy. However, it remains uncertain
whether combining induction with concurrent
chemotherapy takes advantage of the benefits of both
treatments. Studies are currently underway to investigate
the potential superiority of induction chemotherapy
followed by concurrent chemoradiotherapy compared
with concurrent chemoradiotherapy alone.
Radiotherapy waiting times have been a major issue in
the UK [17,18], particularly for HNSCC with rapid
tumour doubling times. During the 2004-5 period
reported here, protracted radiotherapy waiting times of
3 months were common. Therefore, induction che-
motherapy was routinely offered to our patients. This
era was prior to the publication of the data demonstrat-
ing the superiority of induction with TPF [12,13], and
cisplatin and 5-FU was the standard induction regimen.
The patients with tonsil carcinoma reported here
received between 1 and 4 cycles prior to radiotherapy,
although the total number depended upon the wait for
radiotherapy to commence, along with tolerance and
response to treatment. The radical radiotherapy sche-
dules in use at the time were either a conventionally
fractionated 65-70 Gy in 30-35 fractions, or a hypofrac-
tionated accelerated regimen of 55 Gy in 20 fractions.
The latter regimen reflected historical radiotherapy
practice within the UK, and also a pragmatic response
to waiting times. Following guidance from the Royal
College of Radiologists, the hypofractionated schedule is
no longer employed in our centre for locally advanced
HNSCC [24].
With implementation of various measures our radio-
therapy waiting times have now fallen to 4 weeks in line
with the national radiotherapy waiting times target.
Nevertheless, in addition to providing data on the use of
induction chemotherapy to compensate for protracted
waiting times for radiotherapy, this series provides
important data on the tolerability and efficacy of induc-
tion chemotherapy followed by radiotherapy ± concur-
rent chemotherapy outside the setting of clinical trials.
Subjects within clinical trials are almost inevitably a fit-
ter selected subset of patients. A major issue with the
chemo-radiotherapy trials is whether the results, based
upon selected fit patients, can be successfully applied to
patients encountered in routine clinical practice. The
results of institutional series of patients treated outside
clinical trials are invaluable in exploring these issues.
The series of 41 patients reported here, treated in
2004-5, demonstrates that induction chemotherapy can
be successfully combined with concurrent chemora-
diotherapy, without excessive toxicity. Radiotherapy
commenced promptly at a median of 21 days (range
10-42) following the adminstration of the final cycle of
radiotherapy. Therefore, induction chemotherapy did
not preclude the prompt delivery of radiotherapy. Nota-
bly, by contrast with the EORTC/TAX323 trial [13], all
patients in this series completed radiotherapy as
planned. It should be noted that the dose of induction
chemotherapy (cisplatin 80 mg/m2 and 5-FU 800 mg/
m2 days 2-5) is lower than that used in the control arm
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5-FU 1000 mg/m2 days 1-5) [13]. In addition 70% of
patients in our series received only 1-2 cycle of induc-
tion chemotherapy compared with the 3-4 cycles com-
monly delivered within trial protocols [6,12,13]. The
lower number of cycles delivered were due the prag-
matic utilisation of induction chemotherapy due to
radiotherapy waiting times. Although this may now be
regarded as suboptimal induction chemotherapy, the
reduced dose and lower number of cycles delivered may
have particular importance in successfully delivering
subsequent radiotherapy. Gaps in the delivery of radio-
therapy for HNSCC are known to be detrimental to out-
come [25]. No patient in this series experienced a gap of
3 days; this compares with approximately one fifth of
patients experiencing gaps in the delivery of radiother-
apy in concomitant chemoradiotherapy trials [26,27].
Concomitant chemotherapy was given to nearly three-
quarters of the patients in our series. The predominant
reason for not giving concomitant chemotherapy to the
remaining patients was limited performance status due
to progressive symptoms in non-responders to induction
chemotherapy; therefore it can be concluded that induc-
tion chemotherapy did not compromise patient fitness
to commence definitive concurrent chemoradiation.
Two-thirds of patients were able to receive only one
cycle of concomitant chemotherapy due to toxicity.
Compliance is a common problem noted with standard
concurrent cisplatin regimens, with nearly one third of
patients not receiving all concurrent chemotherapy
cycles [28]. Several centres have now adopted two cycles
as standard concomitant treatment due to poor compli-
ance and toxicity [26,29]. In our series, no patient who
was treated with hypofractionated radiotherapy 55 Gy in
20 fractions over 4 weeks received more than one cycle
of concurrent chemotherapy. In our experience it is
uncommon to be able to deliver more than once cycle
of concurrent chemotherapy with hypofractionated
radiotherapy due to significant acute toxicity of the
radiotherapy schedule. However, only 11 of the 26 (42%)
patients receiving conventionally fractionated concomi-
tant chemoradiotherapy received 2 cycles. Decisions on
whether to administer further cycles of concomitant
chemotherapy are based upon clinical assessment of the
patients; potential reasons for not administering further
concomitant chemotherapy include deteriorating patient
fitness, severity of radiotherapy toxicity including muco-
sitis, and previously severe chemotherapy toxicity. In
our practice we would aim to deliver further chemother-
apy if there was a reasonable expectation that this would
not lead to gaps in the delivery of radiotherapy. It is
unclear whether the failure to achieve 2 cycles of con-
current chemotherapy in the majority of patients was
due to the overall toxicity of the concurrent approach
or due to cumulative toxicity from induction
chemotherapy. The number of cycles of concurrent che-
motherapy delivered may be considered inferior to that
achieved in clinical trials. However, this may reflect dif-
ferences in patients treated within and outside of clinical
trials. For example, clinical trials commonly exclude
patients over 70 whilst the series presented here
includes patients receiving concomitant chemoradiother-
apy up to the age of 74.
The overall toxicity of induction chemotherapy fol-
lowed by (chemo)-radiotherapy appears acceptable.
There were no on-treatment deaths; the patient who
died 7 months after treatment with a carotid blow out
w i t h o u te v i d e n c eo fd i s e a s ew a st h eo n l yd e a t hw h i c h
may have been treatment-related. As would be expected,
the majority of patients required enteral feeding during
or shortly after completing treatment. However, on fol-
low-up only 2 of 27 surviving patients had grade 3 dys-
phagia and none was gastrostomy-dependant. These
data compare favourably with other chemoradiotherapy
series; for example in a pooled analysis of three RTOG
trials long term feeding tube dependence was 13% [30].
The tumour outcome of the patients presented here is
excellent, with 85% of patients achieving a complete
tumour response 4 months after completion of therapy.
The timing of post-treatment response assessment varies
between centres. The 4 month timepoint used here is
intended to allow adequate time for post-radiotherapy
response to be complete. In line with this concept, a
recent study has shown that an 8 week response assess-
ment is too early, with more complete responses being
seen at 8 months than 8 weeks post-treatment [29]. For
our cohort of 41 patients, 3 year cause-specific survival
was 75%, and 3 year overall survival of 66%. Importantly
in this context, in locally advanced HNSCC 3 year over-
all survival has been shown to be a good surrogate for
5 year survival [31].
The 3 year PFS for patients receiving induction che-
motherapy followed by radiotherapy alone was 82%
compared with 72% for those treated with induction
chemotherapy followed by concomitant chemoradiother-
apy (Table 4). This difference is not statistically signifi-
cant (p = 0.6). The expectation would be for a superior
PFS outcome for patients receiving concomitant che-
motherapy. However, due to the small numbers of
patients in the group without concomitant treatment (n
= 11), it is not appropriate to draw conclusions regard-
ing the benefit of concomitant chemotherapy based
upon this subgroup comparison.
Table 5 presents the results of this and other sequential
chemoradiotherapy studies. Our induction regime is
almost identical to that used by Royal Marsden Hospital
[32]. Both the studies used similar doses and number of
cycles resulting in overall response in over three-quarters
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no treatment related deaths. Overall survival (OS) in our
study was 66% at 3 years. This figure is superior to that
reported at 2 years by some studies using sequential ther-
apy [12,32,33], and similar to that in other series [34-36].
Whilst it is tempting to compare our results with other
published series, differences in locoregional control and
overall survival are likely to be heavily influenced by the
patient population and tumour stage and tumour subsites
included.
HPV-16 is recognised as a major aetiological factor in
the development of oropharyngeal carcinomas [15],
although the proportion due to HPV varies widely
between geographical areas [37]. The presence of HPV-
16 is a powerful favourable prognostic factor for both
disease control and overall survival [37-39]. In a rando-
mised trial comparing accelerated versus conventional
concomitant chemoradiotherapy in patients with stage
III/IV oropharyngeal squamous cell carcinoma, 3 year
overall survival was similar in both arms (70 v 64%,
non-significant difference). However, 3 year overall sur-
vival for HPV positive tumours was 82% versus 57% for
HPV negative tumours [39]. It remains to be determined
whether HPV is a predictive marker allowing selection
of particular therapeutic strategies [37]. The absence of
data regarding the prevalence of human papilloma virus
(HPV) within our cohort of patients with squamous cell
carcinoma of the tonsil represents a limitation of our
study. As with other studies [32-36], this limits the com-
parison of outcomes between series. The optimal
Table 5 Summary of induction chemotherapy followed by (chemo)-radiotherapy
Leeds RMH, UK
(19)
Posner et al
(15)
Hitt et al (16) Vokes et al (20) Machtay et al (21) Urba et al
(22)
Sequential
theapy (IC +
CRT)
IC: PF 1-4 cycles
CRT (70 Gy in
35# Cisplatin100
m g/m2 day 1,
22, 43)/55 gy
in20# Cisplatin
day 1, 28
IC:P(75 mg/
m 2)5 Fu
(1000 mg/
m2 for 4
days)-2
cycles +
CRT :65 Gy
in 30# with
cisplatin 100
mg/m2 on
day 1 & 29)
Control arm:
IC: cisplatin
(100 mg/m2)
5 FU(1000
mg/m2/day)-5
days
CRT: 70-74 Gy
with weekly
carboplatin
AUC 1.5
Control arm:
IC:3
cisplatin100 m
g/m2 5-
FU1000 mg/
m2-5 days-3
cycles
CRT:7 0g yI N
35#
Cisplatin100
mg/m2 on day
1, 22, 43
IC: Paclitaxel/
carbo platin
weekly × 6
followed by
CRT: paclitaxel, 5-
FU, hydroxyurea
and twice daily
radiation therapy
every other week
IC: caboplatin/pa clitaxel-2
cycles
CRT: 70 in 35f with
Concurrent Weekly
paclitaxel Adjuvant chemo
(2 cycles of carbo/taxol) +
neck dissection in N2/N3
patients
IC: Cisplatin
100 mg/m2, 5
FU 1000 mg/
m2 5 days-2
cycles
CRT: 72 Gy +
cisplatin 100
mg/m2 day 1,
22, 43
Response IC: 78%(overall) IC: 76%
(overall)
IC: 64%
(overall)
IC: 68%(overall) IC: 87%(overall) IC:89%(over all) IC: 76%(overall)
CRT: 85%(CR) CRT: 79%
(CR)
CRT: 78% (CR) CRT:82% (CR) CRT:90% (CR) CRT:54%
histological CR
Overall survival
(OS), disease
free survival
(DFS)
65%(3 YR OS) 63% (2 YR
OS)
48% (3 YR OS) 61.5% (2 YR
OS)
70% (3 YR OS) 70% (3 YR OS) 64%(3 YR OS)
75%(3 YR DFS) 68% (2 YR
DFS)
80% (3 YR DFS)
Logo-
regionalcontrol
(LRC)
91% in complete
responders at 3
yrs
71% at 2 yrs 62% NR 94% (2 YR LRC) 82% at 3 YRS NR
Metastasi s-free
survival
89% AT 3 yrs 91% at 2 yrs 91% NR 93% AT 2 YRS 81% ay 3 YRS NR
Toxicity-Acute
(AC), Late (LT)
Gr3/4 only
IC: neutropenia
10%, mucositis
5%
CRT: 75% skin,
70%mucositis,
dysphagia 63%
Late: 24%
IC:
neutropenia
5%, n&v 3%
CRT:
mucositis
60%,
dysphagia
72%;
Late:8 %
IC:
neutropenia
56%, mucositis
27%
CRT:
mucositis38%,
dysphagia
24%
IC:
neutropenia
36%, mucositis
(gr2-4) 53%
CRT: 4 toxic
deaths
IC:36%
neutropenia
CRT: 76%
mucositis, 61%
skin
CRT: 98%mucositis
Late: 24% Treatment
mortality: 4%
IC: 29% grade4
CRT:19%
grade4
Haematological
No of patients 41 145 246 193 69 53 59
Cancer site/
staging
All Tonsil
All stage 4
Oropharynx
54%
Stage4 60%
Oropharynx
53%
Stage 4 81%
Oropharynx
35%
Stage 4 83%
Oropharynx 44%
Stage 4 96%
All Oropharynx
Stage 4 65%
Oropharynx
62%tongue
base
Stage 4 58%
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material is controversial, with assays including in situ
hybridisation, polymerase chain reaction (PCR) and
immunohistochemistry for p16 as a surrogate marker
[37]. These discussions are currently under investigation
in our institution.
The role of routine neck dissection after chemora-
diotherapy continues to be debated. Some reports [40,41]
have found no survival advantage with neck dissection in
patients who achieved complete response following che-
moradiotherapy. In addition, there is a higher subjective
morbidity in patients undergoing neck dissection [40].
None of the patients in our series with a complete
response following chemoradiotherapy underwent neck
dissection; only one of these 35 patients subsequently
developed an isolated nodal recurrence and subsequently
succumbed to his disease. The s ed a t as u p p o r tt h ev i e w
that a neck dissection can be safely avoided in the
absence of macroscopic residual disease. Further clarifi-
cation of this issue will be provided by the UK National
Cancer Research Institute PET neck study which is cur-
rently recruiting to investigate whether neck dissection
can be safely avoided in locally advanced HNSCC with
N2 or N3 nodal disease who achieve complete locoregio-
nal response following chemoradiotherapy.
The choice of treatment modality for the management
of locally advanced tonsillar cancer remains controver-
sial and varies between centres, some preferring primary
surgery and others non-surgical treatment [16]. The
good outcomes in terms of disease control and accepta-
ble toxicity presented in this series provide support for a
non-surgical approach to treatment.
In summary, the non-surgical treatment of tonsillar
squamous cell carcinomas offers very high rates of locor-
egional control and overall survival. Induction cisplatin-
based chemotherapy can be combined with radical
(chemo-) radiotherapy, without a detrimental effect upon
radiotherapy delivery, and acceptable toxicity. Further
issues remain to be addressed, including the necessity of
both induction and concurrent treatment for tonsillar
tumours with an overall favourable outcome; reduced
treatment intensity may be possible to reduce toxicity
without compromising tumour control. The future of
improving the outcomes of head and neck therapy, in
terms of both tumour control and toxicity, may lie in our
ability to individualise treatment. This will involve the
identification of predictive and prognostic markers,
including HPV status, and understanding the biological
behaviour and outcome of individual tumour subsites.
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